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Summary Metabolic syndrome is deﬁned as an association of central obesity and several
other cardiometabolic risk factors. Dysfunctional visceral adipose tissue and inﬂammatory sta-
tus appear to be involved in its genesis. New deﬁnitions have decreased the threshold for
glycaemia and one has lowered the threshold for waist circumference, leading to an increase
in the prevalence of metabolic syndrome. However, the impact on mortality with these new
deﬁnitions is lower than with the National Cholesterol Education Program—Adult Treatment
Panel III 2001 deﬁnition. An increase in waist circumference, along with increased glycaemia,
triglycerides and/or blood pressure is more highly associated with an increased risk of mortality
than are other associations, while a decrease in high density lipoprotein cholesterol increases
risk of coronary heart disease. The risk of sudden death and stroke is particularly notable with
metabolic syndrome. Metabolic syndrome is associated with an increase in heart rate, pulse
pressure, arterial stiffness and left ventricular hypertrophy, impairment of diastolic function,
enlargement of the left atrium and atrial ﬁbrillation. In the 2007 European recommendations
for the management of high blood pressure, metabolic syndrome is now taken into consider-
ation for both risk stratiﬁcation and in selecting the optimal therapeutic strategy for arterial
hypertension.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé Le syndrome métabolique (SM) associe une obésité centrale et une constellation
de plusieurs facteurs de risque cardiométaboliques. Les élévations du plasminogen activator
inhibitor-1 et de l’aldostérone paraissent jouer un rôle clé dans son développement. Les
nouvelles déﬁnitions, ayant abaissé le seuil du glucose et l’une d’elles ayant abaissé les seuils
du périmètre abdominal tout en exigeant ce critère, ont pour conséquence une prévalence
accrue du SM, mais un impact sur la morbimortalité cardiovasculaire et totale moins élevé
qu’avec la déﬁnition du National Cholesterol Education Program 2001. Le risque de mort subite
est particulièrement marqué. L’augmentation du périmètre abdominal, associé à l’élévation du
glucose, des triglycérides et/ou de la pression artérielle, comporte un risque de mortalité plus
élevé que les autres associations des composants du SM ; la baisse du HDL-cholestérol accentue
le risque coronaire. Le SM est associé à une augmentation de la fréquence cardiaque, de la
pression artérielle pulsée, de la rigidité artérielle, une hypertrophie et une altération de la
fonction diastolique ventriculaire gauche, une dilatation de l’oreillette gauche et une incidence
accrue de ﬁbrillation atriale. Le SM est pris en compte dans les recommandations européennes
2007 concernant la stratiﬁcation du risque et la stratégie thérapeutique de l’hypertension
artérielle.
© 2008 Elsevier Masson SAS. All rights reserved.
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he main physiological processes underlying metabolic
yndrome are insulin resistance [1,2] and inﬂammation
3—5]; lipotoxicity also appears to be a major compo-
ent [6]. Metabolic syndrome associates abdominal obesity
7] and several metabolic factors with elevated blood
ressure levels. It is associated with an increase in car-
iovascular disease (CVD) and death, and in diabetes
8—10]. However, numerous debates have been gener-
ted over the disparity in the deﬁnitions used to describe
etabolic syndrome and its lack of homogeneity, which
ay ultimately question the reality of this syndrome.
he impact on morbidity and mortality of metabolic syn-
rome as a whole, of its individual components, and the
imits chosen for each [11] remain important points of
iscussion.
After the widely used National Cholesterol Education
rogram—Adult Treatment Panel III (NCEP—ATP III) deﬁni-
ion in 2001 [12], two new deﬁnitions were established
y experts in 2005, one by the American Heart Associa-
ion/National Heart, Lung, and Blood Institute Scientiﬁc
tatement (AHA/NHLBI) [13] and the other by the Inter-
ational Diabetes Federation (IDF) [14]. Both of these
eﬁnitions increased the threshold of several components
f metabolic syndrome, including waist circumference for
he IDF deﬁnition. In 2007, the international consensus of
he European Society of Cardiology and the European Soci-
ty of Hypertension (ESC/ESH) summarized the deﬁnition of
etabolic syndrome as a speciﬁc association of three of the
omponents found in each of the three previous deﬁnitions
15].
Numerous studies focus on the prevalence of metabolic
yndrome and its components and on the morbimortality
isks associated with it. Certain pathologies, associated with
etabolic syndrome, have also been discovered recently
nd European recommendations pertaining to blood pres-
ure (BP) management have been updated to take into
ccount metabolic syndrome.
•
•ew deﬁnitions of metabolic syndrome
he AHA/NHLBI 2005 [13] deﬁnition is derived from the
CEP—ATP III 2001 deﬁnition [12] and requires at least three
f the following criteria to be present:
waist circumference greater than or equal to 102 cm in
men and greater or equal to 88 cm in women (W);
triglycerides greater than or equal to 1.50 g/L or a speciﬁc
treatment for elevated triglycerides (TG);
high density lipoprotein (HDL) cholesterol less than
0.40 g/L in men and less than 0.50 g/L in women or a
speciﬁc treatment for reduced HDL cholesterol;
systolic BP greater than or equal to 130mmHg or diastolic
BP greater than or equal to 85mmHg or antihypertensive
treatment (BP);
fasting glucose greater than or equal to 1.00 g/L or drug
treatment for elevated glucose (G).
The changes that were made in 2005 to the NCEP—ATP
II 2001 deﬁnition slightly reduced the threshold for waist
ircumference (it had been strictly greater than 102 cm in
en and greater than 88 cm in women) but signiﬁcantly low-
red the threshold for glucose (it had been greater than or
qual to 1.10 g/L). Furthermore, individuals treated for dys-
ipidaemia, hypertension or hyperglycaemia were included.
onsequently, based on this new deﬁnition, the number of
ubjects and, therefore, the prevalence of metabolic syn-
rome increased.
The IDF deﬁnition [14] requires the presence of abdomi-
al obesity, deﬁned as waist circumference greater than or
qual to 94 cm in men and greater than or equal to 80 cm
n women for Europids (W) and at least two of the following
riteria:
triglycerides greater than or equal to 1.50 g/L or a speciﬁc
treatment for lipid abnormalities (TG);
HDL cholesterol less than 0.40 g/L in men and less than
0.50 g/L in women or a speciﬁc treatment for lipid abnor-
malities (HDL);
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• systolic BP greater than or equal to 130mmHg or diastolic
BP greater than or equal to 85mmHg or antihypertensive
treatment (BP);
• fasting glucose greater than or equal to 1.00 g/L or dia-
betes (G).
The IDF deﬁnition introduces fundamental changes in the
requirements needed for deﬁning metabolic syndrome; it
signiﬁcantly reduces the threshold for waist circumference
and glucose and includes treated individuals and those with
diabetes.
The deﬁnition from the ESC/ESH consensus [15] requires
at least three of the following ﬁve criteria to be present:
• waist circumference greater than 102 cm in men and
greater than 88 cm in women (W);
• systolic BP greater than or equal to 130mmHg or diastolic
BP greater than or equal to 85mmHg (BP);
• HDL cholesterol less than 0.40 g/L in men and less than
0.46 g/L in women (HDL);
• triglycerides greater than or equal to 1.50 g/L (TG);
• fasting glucose greater than or equal to 1.0 g/L (G).
The ESC/ESH deﬁnition includes a combination of criteria
from the NCEP—ATP III 2001 deﬁnition (i.e., abdominal obe-
sity, BP and TG) and new thresholds for HDL cholesterol in
women and for glycaemia since it does not include treatment
for hypoglycaemia or diabetes. The lack of epidemiolog-
ical data available for this deﬁnition is most likely to be
attributed to the fact that it was published only recently.
Concerns and criticisms pertaining to the lack of homo-
geneity among these deﬁnitions remain. Lowering the
thresholds for several of the components and the inclusion
of treated subjects require further studies to determine the
impact of these components on morbidity and mortality risk
for subjects identiﬁed as having metabolic syndrome accord-
ing to these new deﬁnitions.
Prevalence of metabolic syndrome and its
components according to recent
deﬁnitions
Differences in the prevalence of metabolic syndrome
according to recent deﬁnitions are reported in numerous
publications [16—28]. For instance, in the Investigations
préventives et cliniques (IPC, Paris) cohort [29—31], which
included 39,998 men (52.6± 8.3 years) and 20,756 women
(54.7± 9.2 years) who volunteered for a free health check-
up and who had no personal history of CVD, the more recent
deﬁnitions were associated with a higher prevalence of
metabolic syndrome. With the AHA/NHLBI deﬁnition, the
prevalence was 20.0% in men and 13.5% in women; with
the IDF deﬁnition, the prevalence was 26.0% in men and
18.4% in women; and with the NCEP—ATP III 2001 deﬁni-
tion, the prevalence was 11.7% in men and 7.5% in women
[29]. In other studies, the prevalence varied from 8 to 37%
with the NCEP—ATP III 2001 deﬁnition, from 26 to 45% with
the AHA/NHLBI deﬁnition, and from 18 to 57% with the IDF
deﬁnition [16—28,32,33]. The prevalence of metabolic syn-
drome often increases by approximately 50% when the IDF
deﬁnition is used compared with the NCEP—ATP III 2001
deﬁnition. The AHA/NHLBI deﬁnition provides an interme-
b
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iate value. Lorenzo et al. compared the prevalence of
etabolic syndrome in different populations and showed
hat the impact of the different deﬁnitions on prevalence
aried depending on the population characteristics [21].
here is no doubt that this complicates the interpretation
f results found in the numerous studies that have exam-
ned metabolic syndrome. Several studies have continued
o use the NCEP—ATP III 2001 deﬁnition because it has been
alidated the most.
Subjects classiﬁed as having metabolic syndrome using
he NCEP—ATP III 2001 deﬁnition, especially in France, were
ncluded based on BP values for which the thresholds were
elatively low [29—33]. This underlines the importance of
he role played by this particular parameter in the risk asso-
iated with metabolic syndrome [34]. The thresholds for
igh BP have not been modiﬁed in the recent deﬁnitions,
nlike blood glucose, which has been lowered, treated sub-
ects have been included, and waist circumference which
s a required component for the IDF deﬁnition and which
ncludes lower thresholds for Europids. To validate these
eﬁnitions, they must be compared using robust criteria,
uch as all-cause and cardiovascular mortality. In the IPC
opulation, Benetos et al., very recently, suggested that
he two new deﬁnitions (AHA/NHLBI and IDF), although they
ncrease the prevalence of metabolic syndrome, they do not
nable the identiﬁcation of new subjects at risk when com-
ared with the NCEP—ATP III 2001 deﬁnition [35]. Further
tudies are needed to clarify this important point.
Even though it is possible for metabolic syndrome to
nclude ﬁve different components, the recent deﬁnitions
nly require three of the ﬁve to be present. This leads to
signiﬁcant disparity among subjects who have been diag-
osed with metabolic syndrome and creates confusion. For
xample, in the IPC population, the percentage of subjects
ho were included based on the different three-component
ombinations varied from 6.0 to 55.5% depending on the
ombinations and deﬁnitions used [29]. According to the
CEP—ATP III 2001 deﬁnition, only 2.4% of the subjects had
our of the metabolic syndrome components and 0.5% had
ll ﬁve [29,30]. These observations clearly show the lack
f homogeneity among patients diagnosed with metabolic
yndrome.
ardiovascular morbidity and mortality
ssociated with metabolic syndrome
ccording to recent deﬁnitions
sing previous deﬁnitions, morbidity associated with
etabolic syndrome has been clearly established [8—10],
esulting in an increase in incidence of cardiovascular dis-
ase, coronary disease and cerebrovascular disease [9].
hese deﬁnitions have also had an impact on ischaemic
trokes, particularly in women, and have shown a higher
ortality rate in women than in men [10,36,37]. The impact
f the newer deﬁnitions is, however, not quite as clear. Mor-
imortality related to metabolic syndrome is systematically
ower when the newer deﬁnitions are used compared to the
CEP—ATP III 2001 deﬁnition [18—20,24—29].
In the IPC population, the risk of all-cause mortality
as lower when the new deﬁnitions were used; this was
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specially true with the IDF deﬁnition, but remained signif-
cant nonetheless. Compared to subjects without metabolic
yndrome (those with fewer than three criteria) and
fter adjustment for age, sex, tobacco consumption, low-
ensity lipoprotein cholesterol, declared physical activity
nd socioeconomic status, mortality risk associated with
he presence of metabolic syndrome was higher with the
CEP—ATP III 2001 deﬁnition (hazard ratio [HR]: 1.79;
5% conﬁdence interval [CI]: 1.35—2.38) than with the
HA/NHLBI (HR: 1.46; 95% CI: 1.14—1.88) or IDF (HR: 1.32;
5% CI: 1.04—1.67) deﬁnitions [29]. Corresponding values
eported by Katzmarzyk et al. were 1.36 (1.14—1.62), 1.31
1.11—1.54) and 1.26 (1.07—1.49), respectively [19]. In the
PC population, the risk of all-cause mortality was 1.44
1.11—1.87) when the ESC/ESH deﬁnition was used [29].
imilar ﬁndings were reported for normotensive and hyper-
ensive patients [38].
Katzmarzyk et al. reported higher HRs for cardiovascular
ortality: 1.79 (95% CI: 1.35—2.37), 1.67 (1.27—2.19) and
.67 (1.27—2.20) for the NCEP—ATP III 2001, AHA/NHLBI, and
DF deﬁnitions, respectively [19]. In the diabetes epidemi-
logy: collaborative analysis of diagnostic criteria in Europe
DECODE) study, the observed hazard ratios were 1.74 (95%
I: 1.31—2.30), 1.72 (1.31—2.26) and 1.51 (1.15—1.99),
espectively, in men and 1.39 (0.89—2.18), 1.09 (0.70—1.69)
nd 1.53 (0.99—2.36), respectively, in women [20]. In the
PC study, risk of cardiovascular mortality was 2.05 (95%
I: 1.28—3.28) for the NCEP deﬁnition and 1.77 (95% CI
.18—2.64) for the IDF deﬁnition [35]. Occasionally, the IDF
eﬁnition does not predict coronary heart disease risk, even
hough with the NCEP—ATP III 2001 deﬁnition this risk is
igniﬁcant [24,27].
Results from the Paris Prospective Study I recently
howed an increased risk of sudden death related to
etabolic syndrome in a population of 6678 men. When the
CEP—ATP III 2001 deﬁnition was used, the risk of sudden
eath increased by 68% (95% CI: 1.05—2.70), whereas the
isk of non-sudden death only increased by 38% (95% CI:
.95—2.01). When the IDF deﬁnition was used, the hazard
atios were 2.02 (1.30—3.14) and 1.69 (1.20—2.38), respec-
ively [39].
ardiovascular morbidity and mortality
ccording to different combinations of
etabolic-syndrome components
everal studies have suggested that the impact of certain
ombinations of metabolic syndrome components are more
eleterious than others, such as abdominal obesity and
levated TGs [40—42]. In the Framingham study, however,
ilson et al. [43] did not ﬁnd any signiﬁcant difference
n cardiovascular morbimortality risk between the various
ombinations of metabolic syndrome components. Wang et
l. found that certain components by themselves were as
redictive of cardiovascular disease as was metabolic syn-
rome itself [44].
Several recent studies have revealed some very interest-
ng information [29,45,46]. Protopsaltis et al. [45] showed
hat among diabetic subjects without known coronary heart
isease (CHD), the combination of metabolic syndrome com-
a
[
a
t
gL. Guize et al.
onents consisting of diabetes plus hypertension plus low
DL cholesterol was associated with an increased risk of
oronary events. Hong et al. [46] found three metabolic syn-
rome component combinations that led to the highest risk
f CHD:
increased BP and increased glycaemia combined with
lower HDL cholesterol;
an increase in BP, glycaemia and TGs;
increased BP and TGs associated with lower HDL choles-
terol.
In the IPC population, we found that the most deleteri-
us associations pertaining to all-cause mortality risk were,
egardless of deﬁnition used, elevated waist circumference,
lycaemia and triglycerides and/or BP [29]. Our ﬁndings
learly show that an accumulation of metabolic syndrome
omponents is related to an increase in mortality risk. For
xample, when compared to subjects with no components of
etabolic syndrome, the hazard ratio increased from 1.37
NS) in the presence of elevated BP alone to 3.10 when
P and glycaemia were associated, to 3.95 when elevated
aist circumference was included, and to 4.65 when ele-
ated BP, glycaemia, waist circumference and TGs were
ssociated (NCEP—ATP III deﬁnition) [34]. These observa-
ions are similar to those made by Andreadis et al. with
egard to hypertensive subjects [47]. Liu et al. showed that,
mong subjects with either high blood glucose levels or with
iabetes, an increase in risk of CVD was strongly related
o the coexistence of multiple cardiometabolic disorders
48]. Kadota et al. found that glucose intolerance played an
mportant role in CVD mortality and that the combination
f certain factors was deleterious, even without the pres-
nce of obesity [49]. Lastly, Mozzafarian et al. suggested
hat metabolic syndrome itself is of less importance than
levated BP or elevated glycaemia in assessing the over-
ll or cardiovascular prognosis in patients with metabolic
yndrome who are over 65 years of age [50].
ther cardiovascular pathologies
ssociated with metabolic syndrome
everal recent studies have examined the relationships
etween BP, pulse pressure, arterial stiffness and metabolic
yndrome [30,50—57]. The rise in pulse pressure, observed
n the presence of metabolic syndrome [30,52], increases
HD mortality in women and may well be a new metabolic-
yndrome component. In untreated hypertensive subjects,
he presence of metabolic syndrome leads to an increase
n aortic stiffness, as determined by pulse-wave velocity,
ndependently of age and systolic BP [55], conﬁrming the
orks of Schillaci et al. [54]. In Japanese patients with
etabolic syndrome, arterial stiffness was not associated
ith the number of coronary artery lesions [56].
Left ventricular hypertrophy increases in the presence
f metabolic syndrome, independently of hypertension
58—62]. Alterations in left ventricular diastolic function
ppear prematurely and are independent of ventricular mass
60,61]. There is an increased risk of cardiovascular events
nd mortality in the presence of left-ventricular hyper-
rophy and metabolic syndrome, primarily, due to BP and
lycaemia [61,62].
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There is a greater prevalence of subclinical CVD, arterial
and renal disease among subjects with metabolic syndrome
and this association increases the risk of developing under-
lying CVD illnesses.
Metabolic syndrome is associated with risk of atrial ﬁb-
rillation [63,64]. In the IPC population [29—31], metabolic
syndrome is more frequent among subjects with atrial ﬁbril-
lation than among those without and, even more so, among
women than among men: 34.2% versus 7.7% in women,
19.3% versus 10.9% in men. Metabolic syndrome is a risk
factor for atrial ﬁbrillation as shown in a large prospective
observational study [65]. In addition to the metabolic syn-
drome components known to increase the incidence of atrial
ﬁbrillation (hypertension, obesity, hyperglycaemia), other
factors, such as an increase in pulse pressure [66], hyper-
trophy and alterations in left ventricular diastolic function,
atrial dilation [58,64] and sleep apnoea [67,68] may also be
contributing factors.
Various elements, resulting from cardiac abnormalities
associated with stimulating the sympathetic nervous system
[69], as noted by an increase in heart rate [29,30], could
explain the increase in incidence of sudden death [39].
Two biomarkers, plasminogen activator inhibitor-1 (PAI-
1), a ﬁbrinolysis inhibitor, and aldosterone play a role in the
development of metabolic syndrome [70]. PAI-1 is expressed
largely in visceral adipose tissue rather than in subcuta-
neous adipose tissue and is inducible by different factors,
more or less implicated in the components of metabolic
syndrome [71]. Elevated levels of PAI-1 are signiﬁcantly asso-
ciated with a progressive increase in glucose, systolic BP and
triglycerides. Elevated-aldosterone levels are signiﬁcantly
associated with increased BP and lower HDL cholesterol [70].
New European recommendations for BP
management
The data pertaining to the risk associated with metabolic
syndrome were taken into account for the new European
recommendations for the management of BP [15]. In these
new recommendations, metabolic syndrome is included in
the risk stratiﬁcation in the same manner as is the pres-
ence of three or more of the more traditional risk factors
(age, tobacco, dyslipidaemia, heredity) and subclinical tar-
get organ disease (cardiac, arterial, renal) and is at the same
level of importance as the presence of diabetes. Bitherapy
is recommended as ﬁrst-line antihypertensive treatment for
high risk hypertensive subjects, but the use of beta blockers,
especially with a thiazide diuretic is not advised in patients
with metabolic syndrome.
Conclusions
Metabolic syndrome, with all its diverse deﬁnitions, both
old and new, remains heterogeneous as a whole. The
clinical- and subclinical-cardiovascular consequences of
this syndrome are numerous and its impact on cardio-
vascular morbidity and mortality has been conﬁrmed. It
is, however, important to specify the combinations of
the most deleterious components of metabolic syndrome,
which vary depending on the population and the def-
[ase 581
nition used and which can be very useful in clinical
ractice.
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